- $17.26bn
- $19.45bn
- $2.86bn
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Revvity To Acquire Human Cell Design To Advance Human-Relevant Cell Models For Metabolic Disease Drug Discovery
U.S. RESEARCH ROUNDUP-Autodesk, Hubspot, Oracle
Revvity raises annual profit, revenue forecasts on strong diagnostics demand (updated)
Revvity Inc reports results for the quarter ended June 30 - Earnings Summary
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Revvity Q2 revenue beats estimates on diagnostics growth
Danaher's revenue outlook cut, biotech miss overshadow profit forecast lift (updated)
Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise
Danaher falls after cutting annual revenue growth forecast
Brief: Revvity Receives FDA Clearance For Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
Revvity rises after first-quarter profit beat
Revvity trims annual profit, sales forecast to exclude China immunodiagnostics unit (updated)
Revvity rises after first-quarter profit beat